These secondary mutations, which occur during the transition from MGUS to overt MM, target plasmablasts, are associated with increased MYC expression, with sometimes activating mutations of RAS, BRAF or with chromosome 13q deletion. The gene discussed is MYC; the disease is Miyoshi myopathy.